BiopharmaTrend.com

A fresh viewpoint on drug discovery, pharma, and biotech

Subscribe | Become an author | Author LogIn

Website

Contact us at info@biopharmatrend.com to request profile updates/corrections. You must be an official company representative to do so (only requests from corporate emails are accepted).

Atomwise

About

Atomwise uses Deep Learning Neural Networks to help discover new medicines. Atomwise achieves the world’s best results for new drug hit discovery, binding affinity prediction, and toxicity detection. Atomwise predicts drug candidates for pharmaceutical companies, startups, and research institutions.

Year Founded
2012
Geography
Canada based
Funding
$51.345 M
Field/area focus
Chemistry
Patents
2
Therapeutic focus
  • Oncology
  • Infectious Diseases
  • Neuroscience
Data type
  • chemical notations
  • SAR
Business model
  • platform licensing
Drug Discovery Strategy
  • Target-based drug discovery (TDD)
Product type
  • small molecules
Research Use Case
  • Lead Identification

Industry Partnerships

YearPartnerFocus
2014Merck
2015AbbVieconfidential
2017Monsanto
2018PfizerAtomwise will computationally analyze millions of diverse small molecules for each of 3 Pfizer’s identified target proteins using its cutting-edge AI platform to predict those that may bind with high affinity to the selected target proteins.

Posts Mentioning This Company

How Big Pharma Adopts AI To Boost Drug Discovery - Oct. 8, 2018
Biopharma Insights
2018 Brings A Surge Of Activity In The “AI For Drug Discovery” Space - March 15, 2018
Biopharma Insights